Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A children's cancer group study

Blood

Volumn 89, Issue 10, 1997, Pages 3769-3777

  Uckun, Fatih M ^a   Yang, Zhiwen ^b   Sather, Harland ^b   Steinherz, Peter ^b   Nachman, James ^b   Bostrom, Bruce ^b   Crotty, Lisa ^b   Sarquis, Mireille ^b   Ek, Onur ^b   Zeren, Tamer ^b   Tubergen, David ^b   Reaman, Gregory ^b   Gaynon, Paul ^b  

^a University of Minnesota   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL SURVIVAL; COHORT ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; TREATMENT OUTCOME;

EID: 17544385422     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.10.3769     Document Type: Article

References (63)

1. Fraser A, Evan GM: A license to kill. Cell 85:781, 1996
2. Yang E, Korsmeyer SJ: Molecular Thanatopsis: A discourse on the BCL-2 family and cell death. Blood 88:386, 1996
3. Reed JC: Bcl-2 family proteins: Regulators of chemoresistance in cancer. Toxicol Lett 82:155, 1995
4. Boise LH, Gottschalk AR, Quintans J, Thompson CB: Bcl-2 and Bcl-2 related proteins in apoptosis regulation. Curr Top Microbiol Immunol 200:107, 1995
5. Williams GT, Smith CA: Molecular regulation of apoptosis: Genetic controls on cell death. Cell 74:778, 1993
6. Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes hematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440, 1988
7. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348:334, 1990
8. Reed JC, Kitada S, Takayama S, Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5:61, 1994
9. Torigoe T, Millan JA, Takayama S, Taichman R, Miyashita T, Reed JC: BCL-2 inhibits T cell mediated cytolysis of a leukemia cell line. Cancer Res 54:4851, 1994
10. Van Rooij H, Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
11. Smets LA, Van den Berg J, Top B, Van Rooij H, Verwijs-Janssen M: BCL-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 84:1613, 1994
12. Campana D, Coustan-Smith E, Manabe A, Buschle M, Raimondi SC, Behm FG, Ashmun R, Arico M, Biondi A, Pui CH: Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood 81:1025, 1993
13. Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V, Huang Y, Mahoney ME, Bullock G, Bhalla K: High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960, 1994
14. Alnemri ES, Fernandes TF, Haldar S, Croce CM, Litwack G: Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B leukemias. Cancer Res 52:491, 1993
15. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG: The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 88:105, 1994
16. Gala JL, Vermylen C, Cornu G, Ferrant A, Michaux JL, Philippe M, Martiat P: High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt's subtype at presentation, and is not correlated with the prognosis. Ann Hematol 69:17, 1994
17. Coustan-Smith E, Kitanaka A, Pui CH, McNinch L, Evans WE, Raimondi SC, Behm FG, Arico M, Campana D: Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood 87:1140, 1996
18. Gaynon PS, Desai A, Bostrom B, Hutchinson R, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM: Early response to therapy and outcome in childhood acute lymphoblastic leukemia. Cancer (in press)
19. Uckun FM, Reaman G, Steinherz PG, Arthur DC, Sather H, Trigg M, Tubergen D, Gaynon P: Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: A Children's Cancer Group Study. Leuk Lymphoma 24:57, 1996
20. Gaynon PA, Bostrom B, Reaman G, Sather H, Trigg ME, Tubergen DG, Uckun FM: Childrens Cancer Group (CCG) initiatives in childhood acute lymphoblastic leukemia (ALL). Int J Pediatr Hematol Oncol (in press)
21. Miller D, Coccia P, Bleyer W, Lukens JN, Siegel SE, Sather H, Hammond GD: Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Children's Cancer Study Group. J Clin Oncol 7:1807, 1989
22. Gaynon P, Bleyer W, Steinherz P, Finkelstein JZ, Littman P, Miller D, Reaman G, Sather H, Hammond GD: Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 18:273, 1990
23. Janka-Schaub GE, Stuhrk H, Kortum B, Graubner U, Haas RJ, Fobel U, Jurgen H, Spaar HJ, Winkler R: Bone marrow blast count on day 28 as the single most important prognostic factor in childhood non T-cell acute lymphoblastic leukemia. Hematol Blut-transfusion 34:233, 1992
24. Gaynon P, Steinherz P, Bleyer WA, Ablin A, Albo V, Finkelstein J, Grossman N, Littman P, Novak L, Pyesmany A, Reaman G, Sather H, Hammond D: Intensive therapy for children with acute lymphoblastic leukemia and unfavorable presenting features. Lancet 2:921, 1988
25. Steinherz P, Gaynon P, Miller D, Reaman G, Bleyer WA, Finkelstein J, Evans R, Meyers P, Steinherz L, Sather H, Hammond D: Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York Regimen - A new intensive therapy protocol. J Clin Oncol 4:744, 1986
26. Tubergen D, Gilchrist G, O'Brien R, Coccia P, Sather H, Waskerwitz M, Hammond D: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 11:527, 1993
27. Gaynon P, Steinherz P, Bleyer WA, Ablin A, Albo V, Finkelstein J, Grossman N, Novak L, Pyesmany A, Reaman G, Chappell R, Sather H, Hammond D: Improved therapy for children with acute lymphoblastic leukemia and unfavorable features: A follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol 11:2234, 1993
28. Gaynon P, Bleyer WA, Steinherz P, Finkelstein J, Littman P, Miller D, Reaman G, Sather H, Hammond D: Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable features. Am J Pediatr Hematol Oncol 10:42, 1988
29. Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G: CD2 Antigen Expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: A Children's Cancer Group Study. Blood 88:4288, 1996
30. Uckun FM, Song CW: Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood 81:1323, 1993
31. Uckun FM, Gajl-Peczalska KJ, Provisor AJ, Heerema NA: Immunophenotype-karyotype associations in human acute lymphoblastic leukemia. Blood 73:271, 1989
32. Uckun FM, Ledbetter JA: Immunobiologic differences between normal and leukemic human B-cell precursors. Proc Natl Acad Sci USA 85:8603, 1988
33. Uckun FM, Myers DE, Jaszcz W, Haissig S, Gajl-Peczalska K, Ledbetter JA: Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 76:2449, 1990
34. Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska KJ, Song CW, Wick MR, Myers DE, Waddick KG, Ledbetter JA: Detailed studies on expression and function of CD19 surface determinant using B43 monoclonal antibody. Blood 71:13, 1988
35. Uckun FM, Jaszcz W, Chandan-Langlie M, Waddick KG, Gajl-Peczalska K, Song CW: Intrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemia. J Clin Invest 91:1044, 1993
36. Uckun FM, Stewart CF, Reaman G, Chelstrom LM, Jin J, Chandan-Langlie M, Waddick KG, White J, Evans WE: In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 85:2817, 1995
37. Myers DE, Jun X, Waddick KG, Chelstrom LM, Gunther R, Bolen J, Uckun FM: Membrane-associated CD19-Lyn complex is an endogenous p53-independent and bcl-2 independent regulator of apoptois in human B-lineage lymphoma cells. Proc Natl Acad Sci USA 92:9575, 1995
38. Smith I: The AMBIS beta scanning system. Bioessays 3:225, 1985
39. Altweg M, Luthy-Hottenstein J, Grehn M, Von Graevenitz A: Automated analysis of 35-S-methionine labeled proteins by SDS-PAGE as a typing method in a suspected cluster of Serratia marcescens. Zb1 Bakt 271:372, 1989
40. Arzase A, Botta GA, Gesu GP, Schito G: Evaluation of a computer-assisted method of analysing SDS-PAGE protein profiles in tracing a hospital outbreak of Serratia marcescens. J Infect 17:35, 1988
41. Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Tuel-Ahlgren L, Chelstrom LM, Burkhardt A, Bolen J, Myers DE: Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science 267:886, 1995
42. Gaynon PS, Crotty ML, Sather H, Bostrom B, Nachman JB, Steinherz PG, Heerema NA, Sarquis M, Tuel-Ahlgren L, Uckun FM: Expression of BCR-ABL, E2A-PBX1 and MLL-AF4 fusion transcripts in newly diagnosed childhood acute lymphoblastic leukemia: A Children's Cancer Group Initiative. Leuk Lymphoma (in press)
43. Uckun FM, Downing JR, Gunther R, Chelstrom LM, Finnegan D, Land VJ, Borowitz MJ, Carroll AJ, Crist WM: Human t(1; 19)(q23;p13) pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 81:3052, 1993
44. Uckun FM, Downing JR, Chelstrom LM, Gunther R, Ryan M, Simon J, Carroll AJ, Tuel-Ahlgren L, Crist WM: Human t(4; 11) (q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 84:859, 1994
45. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn E, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallon SE, Sather H, Shuster J, Simon R, Trigg M, Uckun F, Ungerleider R: A uniform approach to riskclassification and treatment assignment for children with acute lymphoblastic leukemia (ALL). J Clin Oncol 14:18, 1996
46. Trigg ME, Gaynon P, Uckun FM: Acute lymphoblastic leukemia in children, in Holland JF, Fry E III, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds): Cancer Medicine (ed 4). 1996, p 1
47. Pui CH: Childhood leukemias. N Engl J Med 332:1618, 1995
48. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122, 1994
49. Champlin, R, Gale RP: Acute lymphoblastic leukemia: Recent advances in biology and therapy. Blood 73:2051, 1989
50. Schrappe M, Reiter A, Sauter S et al: Konzeption und Zwishenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukaemie bei Kindern und Jugendlichen: die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark. Klin Padiatr 206:208, 1994
51. Hutchinson R, Bertolone S, Cooper H et al: Early marrow response predicts outcome for patients with low risk ALL. Proc Am Soc Clin Oncol 13:319, 1994 (abstr 1051)
52. Nachman J, Lukens J, Gaynon P et al: Predictors of slow early response (SER) to BFM induction therapy in children and young adults with acute lymphoblastic leukemia (ALL). A report from the Children's Cancer Group (CCG). Blood 80:257a, 1992 (abstr 1018, suppl 1)
53. Hermine O, Haioun C, Lepage E, dÕAgay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P: Prognostic significance of bcl-2 expression in agressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 87:265, 1996
54. Kondo E, Yosino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J, Akagi T: Expression of BCL-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 145:330, 1994
55. Smith MR, Abubakr Y, Mohammad R, Xie T, Hamdan M, al-Katib A: Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodg-kin's lymphoma cell line WSU-FSCCL. Cancer Gene Ther 2:207, 1995
56. Kitada S, Takayama S, De Riel K, Tanaka S, Reed JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4:71, 1994
57. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9:3049, 1994
58. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K, Wong L, Janossy G: BCL-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia 9:1191, 1995
59. Russell NH, Hunter AE, Bradbury D, Zhu YM, Keith F: Biological features of leukemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukemia. Leuk Lymphoma 16:223, 1995
60. Campos L, Sabido O, Rouault JP, Guyotat D: Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84:595, 1994
61. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
62. Bleyer WA: What can be learned about childhood cancer from "Cancer Statistics Review 1973-1988". Cancer 71:3229, 1993
63. Young JL, Gloeckler Ries L, Silverberg E, Horm JW, Miller RW: Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 58:598, 1986